2023 Q4 Form 10-Q Financial Statement

#000107997323001561 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $629.0K $660.0K $866.5K
YoY Change 3.54% -23.83% 76.43%
% of Gross Profit
Research & Development $7.431K $8.299K $28.44K
YoY Change -50.94% -70.82% -53.98%
% of Gross Profit
Depreciation & Amortization $460.00 $461.00 $330.00
YoY Change 16.75% 39.7% 32.0%
% of Gross Profit
Operating Expenses $643.9K $675.0K $895.3K
YoY Change -0.34% -24.6% 61.84%
Operating Profit -$643.9K -$675.0K -$895.3K
YoY Change -0.34% -24.6% 61.84%
Interest Expense -$74.68K -$70.00K $26.10K
YoY Change -187.57% -368.25% -123.57%
% of Operating Profit
Other Income/Expense, Net -$74.68K -$70.53K -$24.16K
YoY Change -11.0% 191.94% -78.17%
Pretax Income -$718.6K -$750.0K -$919.4K
YoY Change -1.56% -18.43% 38.49%
Income Tax
% Of Pretax Income
Net Earnings -$718.6K -$745.5K -$919.4K
YoY Change -1.56% -18.91% 38.6%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.02 -$0.02
Diluted Earnings Per Share -$0.01 -$0.02 -$21.16K
COMMON SHARES
Basic Shares Outstanding 48.80M shares 48.70M shares 43.42M shares
Diluted Shares Outstanding 48.75M shares 48.62M shares 43.45M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $384.7K $140.0K $1.898M
YoY Change -65.07% -92.62% -52.1%
Cash & Equivalents $384.7K $140.4K $1.898M
Short-Term Investments
Other Short-Term Assets $9.390K $30.00K $135.3K
YoY Change -88.04% -77.82% 48.14%
Inventory
Prepaid Expenses $3.394K $16.28K $134.3K
Receivables
Other Receivables
Total Short-Term Assets $394.1K $162.6K $2.033M
YoY Change -66.6% -92.0% -49.84%
LONG-TERM ASSETS
Property, Plant & Equipment $9.111M $7.621M $3.249M
YoY Change 137.5% 134.58% 5091.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $9.177M $7.701M $3.381M
YoY Change 131.96% 127.74% 5303.47%
TOTAL ASSETS
Total Short-Term Assets $394.1K $162.6K $2.033M
Total Long-Term Assets $9.177M $7.701M $3.381M
Total Assets $9.571M $7.863M $5.415M
YoY Change 86.35% 45.22% 31.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.648M $1.270M $549.4K
YoY Change 406.04% 131.15% 156.46%
Accrued Expenses $76.50K $80.00K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $250.0K $0.00
YoY Change -100.0%
Total Short-Term Liabilities $4.200M $2.418M $1.204M
YoY Change 239.39% 100.88% -89.24%
LONG-TERM LIABILITIES
Long-Term Debt $1.740M $1.680M $5.212M
YoY Change -67.17% -67.77% 6.53%
Other Long-Term Liabilities $0.00 $10.00K $132.1K
YoY Change -100.0% -92.43%
Total Long-Term Liabilities $1.740M $1.690M $5.344M
YoY Change -67.99% -68.38% 9.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.200M $2.418M $1.204M
Total Long-Term Liabilities $1.740M $1.690M $5.344M
Total Liabilities $5.940M $4.115M $6.548M
YoY Change -10.99% -37.16% -59.37%
SHAREHOLDERS EQUITY
Retained Earnings -$128.7M -$128.0M -$125.0M
YoY Change 2.39% 2.41%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.593M $3.711M -$1.171M
YoY Change
Total Liabilities & Shareholders Equity $9.571M $7.863M $5.415M
YoY Change 86.35% 45.22% 31.55%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$718.6K -$745.5K -$919.4K
YoY Change -1.56% -18.91% 38.6%
Depreciation, Depletion And Amortization $460.00 $461.00 $330.00
YoY Change 16.75% 39.7% 32.0%
Cash From Operating Activities -$50.65K -$395.4K -$1.316M
YoY Change -91.64% -69.95% 275.97%
INVESTING ACTIVITIES
Capital Expenditures $323.8K $164.4K $322.7K
YoY Change -22.31% -49.05% -4408.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$323.8K -$164.4K -$322.7K
YoY Change -22.31% -49.05% 4208.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 623.2K $74.24K $376.1K
YoY Change 175.49% -80.26% 263.41%
NET CHANGE
Cash From Operating Activities -50.65K -$395.4K -$1.316M
Cash From Investing Activities -323.8K -$164.4K -$322.7K
Cash From Financing Activities 623.2K $74.24K $376.1K
Net Change In Cash 248.8K -$485.6K -$1.262M
YoY Change -131.23% -61.53% 397.05%
FREE CASH FLOW
Cash From Operating Activities -$50.65K -$395.4K -$1.316M
Capital Expenditures $323.8K $164.4K $322.7K
Free Cash Flow -$374.5K -$559.9K -$1.639M
YoY Change -63.39% -65.83% 378.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 dei Entity Central Index Key
EntityCentralIndexKey
0000875729
CY2023Q3 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2023Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
usd
CY2023Q3 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q3 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022Q3 bnet Conversion Of Debt And Liabilities Into Common Units
ConversionOfDebtAndLiabilitiesIntoCommonUnits
usd
CY2023Q3 bnet Conversion Of Debt And Liabilities Into Notes Payable
ConversionOfDebtAndLiabilitiesIntoNotesPayable
usd
CY2023Q3 bnet Conversion Of Deferred Compensation To Notes Payable
ConversionOfDeferredCompensationToNotesPayable
usd
CY2023Q3 bnet Conversion Of Notes Payable Into Shares
ConversionOfNotesPayableIntoShares
usd
CY2022Q3 bnet Purchase Of Property And Equipment For Accounts Payable
PurchaseOfPropertyAndEquipmentForAccountsPayable
usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q3 dei Document Type
DocumentType
10-Q
CY2023Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q3 dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
CY2023Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q3 dei Entity File Number
EntityFileNumber
000-19333
CY2023Q3 dei Entity Registrant Name
EntityRegistrantName
Bion Environmental Technologies, Inc.
CY2023Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CO
CY2023Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1176672
CY2023Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
9 East Park Court
CY2023Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Old Bethpage
CY2023Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11804
CY2023Q3 dei City Area Code
CityAreaCode
516
CY2023Q3 dei Local Phone Number
LocalPhoneNumber
586-5643
CY2023Q3 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q3 dei Trading Symbol
TradingSymbol
BNET
CY2023Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q3 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48796247 shares
CY2023Q3 us-gaap Cash
Cash
140353 usd
CY2023Q2 us-gaap Cash
Cash
625964 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16280 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16785 usd
CY2023Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
6000 usd
CY2023Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
6000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
162633 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
648749 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
80188 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
93875 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7620661 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6851009 usd
CY2023Q3 us-gaap Assets
Assets
7863482 usd
CY2023Q2 us-gaap Assets
Assets
7593633 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1269482 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
677136 usd
CY2023Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1073708 usd
CY2023Q2 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
864781 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
75000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
75000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2418190 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1616917 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12784 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29068 usd
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1683966 usd
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1715970 usd
CY2023Q3 us-gaap Liabilities
Liabilities
4114940 usd
CY2023Q2 us-gaap Liabilities
Liabilities
3361955 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49485556 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48880237 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48781247 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48175928 shares
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132197829 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131935418 usd
CY2023Q3 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
504650 usd
CY2023Q2 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
504650 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127982210 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-127236663 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
3710969 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
4194105 usd
CY2023Q3 us-gaap Minority Interest
MinorityInterest
37573 usd
CY2023Q2 us-gaap Minority Interest
MinorityInterest
37573 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3748542 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4231678 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7863482 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7593633 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
666255 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
866494 usd
CY2023Q3 us-gaap Depreciation
Depreciation
461 usd
CY2022Q3 us-gaap Depreciation
Depreciation
330 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8299 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28443 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
675015 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
895267 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-675015 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-895267 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
154933 usd
CY2023Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
27987 usd
CY2023Q3 us-gaap Interest Income Operating
InterestIncomeOperating
395 usd
CY2022Q3 us-gaap Interest Income Operating
InterestIncomeOperating
1935 usd
CY2023Q3 bnet Interests Expense
InterestsExpense
70927 usd
CY2022Q3 bnet Interests Expense
InterestsExpense
26095 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-70532 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-24160 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-745547 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-919427 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-745547 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-919427 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48617675 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48617675 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43451846 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43451846 shares
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-894579 usd
CY2022Q3 bnet Sale Of Units Value
SaleOfUnitsValue
320000 usd
CY2022Q3 bnet Warrants Exercised For Common Shares
WarrantsExercisedForCommonShares
56125 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
80000 usd
CY2022Q3 bnet Issuance Of Warrants For Services
IssuanceOfWarrantsForServices
15000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
50000 usd
CY2022Q3 bnet Adjustment To Additional Paid In Capital Modification Of Warrants
AdjustmentToAdditionalPaidInCapitalModificationOfWarrants
159433 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-919427 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1133448 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
4231678 usd
CY2023Q3 bnet Sale Of Units Value
SaleOfUnitsValue
45742 usd
CY2023Q3 bnet Warrants Exercised For Common Shares
WarrantsExercisedForCommonShares
28500 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
27987 usd
CY2023Q3 bnet Vesting Of Options For Employees And Services
VestingOfOptionsForEmployeesAndServices
55108 usd
CY2023Q3 bnet Vesting Of Warrants For Employees And Services
VestingOfWarrantsForEmployeesAndServices
3281 usd
CY2023Q3 bnet Debt Modification
DebtModification
-8430 usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
49048 usd
CY2023Q3 bnet Adjustment To Additional Paid In Capital Modification Of Warrants
AdjustmentToAdditionalPaidInCapitalModificationOfWarrants
61175 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-745547 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3748542 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-745547 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-919427 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
461 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
330 usd
CY2023Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
70927 usd
CY2022Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
26096 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
58389 usd
CY2022Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
95000 usd
CY2023Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-505 usd
CY2022Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-23297 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-8071 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-787276 usd
CY2023Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2596 usd
CY2022Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
16155 usd
CY2023Q3 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
202500 usd
CY2022Q3 us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
75000 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-395445 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1315892 usd
CY2023Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
164408 usd
CY2022Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
322694 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-164408 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-322694 usd
CY2023Q3 bnet Proceeds From Sale Of Units
ProceedsFromSaleOfUnits
45742 usd
CY2022Q3 bnet Proceeds From Sale Of Units
ProceedsFromSaleOfUnits
320000 usd
CY2023Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
28500 usd
CY2022Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
56125 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
74242 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
376125 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-485611 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1262461 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
625964 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3160442 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140353 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1897981 usd
CY2023Q3 bnet Conversion Of Debt And Liabilities Into Common Units
ConversionOfDebtAndLiabilitiesIntoCommonUnits
49048 usd
CY2022Q3 bnet Conversion Of Debt And Liabilities Into Notes Payable
ConversionOfDebtAndLiabilitiesIntoNotesPayable
23943 usd
CY2022Q3 bnet Conversion Of Deferred Compensation To Notes Payable
ConversionOfDeferredCompensationToNotesPayable
20000 usd
CY2022Q3 bnet Conversion Of Notes Payable Into Shares
ConversionOfNotesPayableIntoShares
50000 usd
CY2023Q3 bnet Purchase Of Property And Equipment For Accounts Payable
PurchaseOfPropertyAndEquipmentForAccountsPayable
600416 usd
CY2023Q3 bnet Cattle Per Head
CattlePerHead
300 decimal
CY2023Q3 bnet Techwastage
Techwastage
1500 decimal
CY2022Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2665500 usd
CY2022Q1 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.25 pure
CY2022Q1 bnet Debt Instrument Periodic Payments
DebtInstrumentPeriodicPayments
666375 usd
CY2022Q1 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.25 pure
CY2022Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.25 pure
CY2023Q1 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
533100 usd
CY2023Q2 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
83275 usd
CY2023Q2 bnet Aggregate Payment
AggregatePayment
2615500 usd
CY2023Q3 bnet Purchase Order
PurchaseOrder
50000 usd
CY2023Q3 bnet Additional Interest Costs Incurred Capitalized
AdditionalInterestCostsIncurredCapitalized
5018760 usd
CY2023Q3 bnet Interest Costs Capitalized Paid
InterestCostsCapitalizedPaid
7044902 usd
CY2023Q3 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
220053 usd
CY2023Q3 us-gaap Interest Costs Incurred
InterestCostsIncurred
6784813 usd
CY2023Q3 bnet Percentage Of Sustainable
PercentageOfSustainable
0.295 pure
CY2023Q3 bnet Description Of Kreider2 Poultry Project
DescriptionOfKreider2PoultryProject
Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA).
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
8291000 usd
CY2023 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
3189000 usd
CY2022 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
10235000 usd
CY2022 bnet Gain On Sale Of Domain Amount
GainOnSaleOfDomainAmount
902000 usd
CY2023 bnet Reduction Of Debt
ReductionOfDebt
3516000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
746000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
919000 usd
CY2023Q3 bnet Working Capital
WorkingCapital
2181000 usd
CY2023Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
3717000 usd
CY2023 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
4038000 usd
CY2022 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1737000 usd
CY2023Q3 bnet Payments To Warrant Exercises Commissions
PaymentsToWarrantExercisesCommissions
86000 usd
CY2022Q3 bnet Payments To Warrant Exercises Commissions
PaymentsToWarrantExercisesCommissions
19000 usd
CY2023Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
74000 usd
CY2022Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
376000 usd
CY2018 bnet Deferred Compensation Liability Amount Cancelled
DeferredCompensationLiabilityAmountCancelled
2404000 usd
CY2023Q3 bnet Reduction Of Debt
ReductionOfDebt
3516000 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zQRr4zt5awB6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zg6an19HNE1">Concentrations of credit risk:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2023Q3 bnet Shares Issued Beginning Of Period
SharesIssuedBeginningOfPeriod
48880237 shares
CY2022Q3 bnet Shares Issued Beginning Of Period
SharesIssuedBeginningOfPeriod
43758820 shares
CY2023Q3 bnet Shares Held By Subsidiaries
SharesHeldBySubsidiaries
-704309 shares
CY2022Q3 bnet Shares Held By Subsidiaries
SharesHeldBySubsidiaries
-704309 shares
CY2023Q3 bnet Shares Outstanding Beginning Of Period
SharesOutstandingBeginningOfPeriod
48175928 shares
CY2022Q3 bnet Shares Outstanding Beginning Of Period
SharesOutstandingBeginningOfPeriod
43054511 shares
CY2023Q3 bnet Weighted Average Shares Issued During Period
WeightedAverageSharesIssuedDuringPeriod
441747 shares
CY2022Q3 bnet Weighted Average Shares Issued During Period
WeightedAverageSharesIssuedDuringPeriod
397335 shares
CY2023Q3 bnet Weighted Average Number Of Diluted Share Outstanding
WeightedAverageNumberOfDilutedShareOutstanding
48617675 shares
CY2022Q3 bnet Weighted Average Number Of Diluted Share Outstanding
WeightedAverageNumberOfDilutedShareOutstanding
43451846 shares
CY2023Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_842_eus-gaap--UseOfEstimates_zmNu4yQoXiEh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86B_z3TT59FRHrK6">Use of estimates:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p>
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7633029 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6862916 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12368 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11907 usd
CY2023Q3 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
7620661 usd
CY2023Q2 us-gaap Property Plant And Equipment Other Net
PropertyPlantAndEquipmentOtherNet
6851009 usd
CY2023Q3 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
217269 usd
CY2022Q3 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
62688 usd
CY2023Q3 bnet Non Cash Compensation
NonCashCompensation
135648 usd
CY2022Q3 bnet Non Cash Compensation
NonCashCompensation
135648 usd
CY2023Q3 us-gaap Depreciation
Depreciation
461 usd
CY2022Q3 us-gaap Depreciation
Depreciation
330 usd
CY2023Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
1073708 usd
CY2022Q3 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
654349 usd
CY2023Q3 bnet Interest Rate On Deferred Compensation
InterestRateOnDeferredCompensation
0.04 pure
CY2023Q3 bnet Deferred Compensation Consecutive Trading Days
DeferredCompensationConsecutiveTradingDays
P10D
CY2023Q3 us-gaap Deferred Compensation Liability Current And Noncurrent
DeferredCompensationLiabilityCurrentAndNoncurrent
192500 usd
CY2022Q3 us-gaap Deferred Compensation Liability Current And Noncurrent
DeferredCompensationLiabilityCurrentAndNoncurrent
50000 usd
CY2021Q3 us-gaap Assets
Assets
297 usd
CY2021Q3 us-gaap Liabilities
Liabilities
10154334 usd
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9939148 usd
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
214235 usd
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
950 usd
CY2021Q4 us-gaap Liabilities
Liabilities
10234501 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10009802 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
212263 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12436 usd
CY2023Q3 us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
10234501 usd
CY2021Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
9868495 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
3470000 usd
CY2023Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.50
CY2023Q3 us-gaap Costs Incurred Development Costs
CostsIncurredDevelopmentCosts
71646 usd
CY2022Q3 us-gaap Costs Incurred Development Costs
CostsIncurredDevelopmentCosts
30688 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
3470000 usd
CY2023Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
3470000 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
3522000 usd
CY2023 bnet Reduction Of Additional Paid In Capital
ReductionOfAdditionalPaidInCapital
14051 usd
CY2023Q3 bnet Debt Modifications
DebtModifications
8430 usd
CY2023Q3 bnet Shares Held By Subsidiaries
SharesHeldBySubsidiaries
-704309 shares
CY2023Q3 bnet Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
38000 shares
CY2023Q3 bnet Common Stock Shares Issued Upon Exercise Of Warrants
CommonStockSharesIssuedUponExerciseOfWarrants
38000 shares
CY2023Q3 bnet Total Proceeds
TotalProceeds
28500 usd
CY2023Q3 bnet Exercise Bonus
ExerciseBonus
0.75 pure
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
23000000 shares
CY2023Q3 bnet Sale Of Warrants
SaleOfWarrants
1003590 shares
CY2023Q3 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1.25
CY2023Q3 us-gaap Shares Issued
SharesIssued
501795 shares
CY2023Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2023-10-01
CY2023Q3 bnet Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
38000 shares
CY2023Q3 bnet Common Stock Shares Issued Upon Exercise Of Warrants
CommonStockSharesIssuedUponExerciseOfWarrants
38000 shares
CY2023Q3 bnet Warrants Exercised For Common Stock
WarrantsExercisedForCommonStock
28500 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12006600 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.85
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y9M29D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5085659 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12006600 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.85
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P1Y6M25D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3387603 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0 usd
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
0 usd
CY2022Q2 bnet Compensation Increased
CompensationIncreased
25000 usd
CY2021Q2 bnet Exercise Price
ExercisePrice
0.75 pure
CY2021 bnet Warrants Held By Trust Owned
WarrantsHeldByTrustOwned
3000000 usd
CY2023Q3 bnet Warrants And Right Outstanding
WarrantsAndRightOutstanding
19659372 shares
CY2022Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2665500 usd
CY2022Q1 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.25 pure
CY2022Q1 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
666375 usd
CY2022Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.25 pure
CY2023Q1 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
533100 usd
CY2023Q2 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
83275 usd
CY2023Q2 bnet Aggregate Payment
AggregatePayment
2615500 usd
CY2023Q3 bnet Purchase Order
PurchaseOrder
50000 usd
CY2023Q3 us-gaap Interest Costs Incurred Capitalized
InterestCostsIncurredCapitalized
5018730 usd
CY2023Q3 bnet Interest Costs Capitalized Paid
InterestCostsCapitalizedPaid
7044902 usd
CY2023Q3 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
220053 usd
CY2023Q3 us-gaap Interest Costs Incurred
InterestCostsIncurred
6784813 usd
CY2022Q1 bnet Sale Of Domain Description
SaleOfDomainDescription
the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.
CY2021Q4 us-gaap Long Term Construction Loan Current
LongTermConstructionLoanCurrent
10010000 usd
CY2021Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
2255802 usd
CY2021Q3 us-gaap Assets
Assets
297 usd
CY2021Q3 us-gaap Liabilities
Liabilities
10154334 usd
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9939148 usd
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
214235 usd
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
950 usd
CY2021Q4 us-gaap Liabilities
Liabilities
10234501 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10009802 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
212263 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12436 usd
CY2023Q3 us-gaap Extinguishment Of Debt Gain Loss Net Of Tax
ExtinguishmentOfDebtGainLossNetOfTax
10234501 usd
CY2021Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
9868495 usd
CY2023Q2 bnet Bank Account Hacked Amount
BankAccountHackedAmount
75000 usd
CY2023Q3 bnet Operating Leases Future Minimum Payment Receivable In Two Years
OperatingLeasesFutureMinimumPaymentReceivableInTwoYears
18750 usd
CY2023Q3 bnet Operating Leases Future Minimum Payment Receivable In Three Years
OperatingLeasesFutureMinimumPaymentReceivableInThreeYears
75000 usd
CY2023Q3 bnet Undiscounted Cash Flow
UndiscountedCashFlow
93750 usd
CY2023Q3 bnet Less Imputed Interest
LessImputedInterest
-5966 usd
CY2023Q3 bnet Capital Leases Contingent Rental Payment Due
CapitalLeasesContingentRentalPaymentDue
87784 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M29D
CY2023Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.10 pure
CY2023Q4 bnet Deferred Compensation Amount
DeferredCompensationAmount
80767 usd
CY2023Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
117553 usd
CY2023Q4 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
235106 shares
CY2023Q3 bnet Sale Of Warrants
SaleOfWarrants
1003590 shares
CY2023Q3 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1.25
CY2023Q3 us-gaap Shares Issued
SharesIssued
501795 shares
CY2023Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2023-10-01

Files In Submission

Name View Source Status
0001079973-23-001561-index-headers.html Edgar Link pending
0001079973-23-001561-index.html Edgar Link pending
0001079973-23-001561.txt Edgar Link pending
0001079973-23-001561-xbrl.zip Edgar Link pending
bion_10q.htm Edgar Link pending
bnet-20230930.xsd Edgar Link pending
ex31x1.htm Edgar Link pending
ex31x2.htm Edgar Link pending
ex32x1.htm Edgar Link pending
ex32x2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
bnet-20230930_cal.xml Edgar Link unprocessable
bnet-20230930_def.xml Edgar Link unprocessable
bnet-20230930_lab.xml Edgar Link unprocessable
bnet-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bion_10q_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending